載入...
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial
IMPORTANCE: Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients. OBJECTIVE: To demonstrate that galcanezumab is superior to placebo in the pr...
Na minha lista:
| 發表在: | JAMA Neurol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Medical Association
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6143119/ https://ncbi.nlm.nih.gov/pubmed/29813147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2018.1212 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|